- Home
- SACH vs CYCC Comparison
SACH vs CYCC Comparison
Compare SACH & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- CYCC
- Stock Information
- Founded
- SACH 2010
- CYCC 1992
- Country
- SACH United States
- CYCC Malaysia
- Employees
- SACH N/A
- CYCC N/A
- Industry
- SACH Real Estate Investment Trusts
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- CYCC Health Care
- Exchange
- SACH Nasdaq
- CYCC Nasdaq
- Market Cap
- SACH 47.8M
- CYCC 47.6M
- IPO Year
- SACH 2017
- CYCC N/A
- Fundamental
- Price
- SACH $0.98
- CYCC $3.59
- Analyst Decision
- SACH Hold
- CYCC Strong Buy
- Analyst Count
- SACH 3
- CYCC 1
- Target Price
- SACH $2.25
- CYCC $11.00
- AVG Volume (30 Days)
- SACH 198.9K
- CYCC 7.3M
- Earning Date
- SACH 05-01-2025
- CYCC 05-20-2025
- Dividend Yield
- SACH 18.35%
- CYCC 4.18%
- EPS Growth
- SACH N/A
- CYCC N/A
- EPS
- SACH N/A
- CYCC N/A
- Revenue
- SACH N/A
- CYCC $43,000.00
- Revenue This Year
- SACH N/A
- CYCC $137.21
- Revenue Next Year
- SACH N/A
- CYCC N/A
- P/E Ratio
- SACH N/A
- CYCC N/A
- Revenue Growth
- SACH N/A
- CYCC N/A
- 52 Week Low
- SACH $0.96
- CYCC $0.17
- 52 Week High
- SACH $3.24
- CYCC $4.41
- Technical
- Relative Strength Index (RSI)
- SACH 42.09
- CYCC 42.95
- Support Level
- SACH $0.96
- CYCC $4.55
- Resistance Level
- SACH $1.05
- CYCC $5.55
- Average True Range (ATR)
- SACH 0.04
- CYCC 1.13
- MACD
- SACH -0.00
- CYCC 0.01
- Stochastic Oscillator
- SACH 19.91
- CYCC 3.59
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.